ibrutinib
janssen,abbvie
[]
as martin dreyling highlighted, 99% of patients on placebo arm had aes and 66% grade 3/4 aes, emphasising the importance of controlled trials &amp; the fallibility of ae attribution #17icml 
haematology registrar | @harvardmed fellow @PORTAL_research | evidence-based medicine & policy | lymphoma | myeloma | Fulbright | writer | SoMe Ed @BrJHaem